SRZN
Surrozen IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$297.85M
P/E Ratio
—
EPS
$-32.37
Beta
0.52
52W High
$29.99
52W Low
$5.90
50-Day MA
$25.45
200-Day MA
$16.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Surrozen Inc
Surrozen Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address severe diseases, leveraging its proprietary SIRPa-IgG platform for targeted immune response modulation. The company's robust pipeline includes groundbreaking antibody therapeutics primarily aimed at oncology and autoimmune disorders, reflecting its commitment to fulfilling significant unmet medical needs. Bolstered by strategic partnerships and a strong emphasis on research and development, Surrozen is strategically positioned to advance transformative therapies, marking it as a promising player within the biopharmaceutical landscape with substantial growth potential.
Fundamentals
| Revenue (TTM) | $3.48M |
| Gross Profit (TTM) | $-25.89M |
| EBITDA | $-41.55M |
| Operating Margin | -2394.00% |
| Return on Equity | -62.80% |
| Return on Assets | -35.70% |
| Revenue/Share (TTM) | $0.47 |
| Book Value | $-19.21 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | 85.66 |
| EV/Revenue | 68.91 |
| EV/EBITDA | 0.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -19.40% |
| Shares Outstanding | $11.49M |
| Float | $5.42M |
| % Insiders | 3.09% |
| % Institutions | 94.44% |
Historical Volatility
HV 10-Day
72.62%
HV 20-Day
59.55%
HV 30-Day
63.97%
HV 60-Day
76.82%
HV Rank
31.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($38.75 target)
4
BuyData last updated: 4/9/2026